ライフサイエンスコーパス: mucosal immune response

1 the ongoing inflammation associated with the mucosal immune response.

2 obacter pylori infection causes a Th1-driven mucosal immune response.

3 ytes into the stomach and the launching of a mucosal immune response.

4 nterferon (IFN), a cytokine important in the mucosal immune response.

5 d is not the optimum route for stimulating a mucosal immune response.

6 dogenous IL-10 is a central regulator of the mucosal immune response.

7 e is the dominant site for the initiation of mucosal immune response.

8 -6/CCR-9, both in T cell development and the mucosal immune response.

9 he induction of both a systemic and a common mucosal immune response.

10 ease (IBD) is associated with a dysregulated mucosal immune response.

11 tiology that are associated with an aberrant mucosal immune response.

12 innate and specific, which organise the host mucosal immune response.

13 ant vaccination site to produce a protective mucosal immune response.

14 sting that HIV-1 vaccines may need to elicit mucosal immune responses.

15 l antigen delivery typically fails to induce mucosal immune responses.

16 by CD4+ T cells dictates the outcome of the mucosal immune responses.

17 tribution of MC in boosting the Th17 axis in mucosal immune responses.

18 detailed analysis of humoral, cellular, and mucosal immune responses.

19 ctococcal vaccines for inducing systemic and mucosal immune responses.

20 tive bacteria and are active participants in mucosal immune responses.

21 (Th2) that generate cytokines implicated in mucosal immune responses.

22 rds the generation of cellular, humoral, and mucosal immune responses.

23 sized to target IgA plasma cells involved in mucosal immune responses.

24 K/RANKL interactions during the induction of mucosal immune responses.

25 ntegrated yet distinct nature of systemic vs mucosal immune responses.

26 2 may be a simple way to augment tolerogenic mucosal immune responses.

27 transfer model of Th1- and Th2-mediated lung mucosal immune responses.

28 the critical first step in the induction of mucosal immune responses.

29 ining the integrity of the epithelium and in mucosal immune responses.

30 tor (GLP-1R) signaling network that controls mucosal immune responses.

31 iological processes as well as in regulating mucosal immune responses.

32 tinal epithelial cell (IEC) participation in mucosal immune responses.

33 ggesting that protection was due to specific mucosal immune responses.

34 enhance envelope (Env)-specific humoral and mucosal immune responses.

35 l cells (IEC) as antigen-presenting cells in mucosal immune responses.

36 us, gp180 appears to be a novel regulator of mucosal immune responses.

37 an effective means of inducing systemic and mucosal immune responses.

38 y regulate the entry of antigen required for mucosal immune responses.

39 nic NP platforms engender potent humoral and mucosal immune responses.

40 ely poor in generating potent and long-lived mucosal immune responses.

41 djuvants for vaccines to induce systemic and mucosal immune responses.

42 h the mucoadhesive polymer chitosan enhances mucosal immune responses.

43 d for disease progression, HIV shedding, and mucosal immune responses.

44 epithelial cells, colonic inflammation, and mucosal immune responses.

45 e in the control of T cell activation during mucosal immune responses.

46 g CD69 plays an important role in regulating mucosal immune responses.

47 was ubiquitously expressed on cells vital to mucosal immune responses.

48 minths influence intestinal inflammation and mucosal immune responses.

49 We aimed to investigate the role of CD69 in mucosal immune responses.

50 o in regulating both metabolic processes and mucosal immune responses.

51 ude vaccines that elicit durable, protective mucosal immune responses.

52 n pre-determining the type and robustness of mucosal immune responses.

53 C and CD4(+) T cells via TL, which modulates mucosal immune responses.

54 cule, transferrin, can significantly enhance mucosal immune responses.

55 onships and role of NK and LTi-like cells in mucosal immune responses.

56 ort to develop vaccines capable of eliciting mucosal immune responses.

57 of the intestinal epithelium is critical for mucosal immune responses.

58 mmediate-early-gene expression in regulating mucosal immune responses.

59 , would be expected to decrease their ocular mucosal immune responses.

60 toxin (CT) is a potent adjuvant for inducing mucosal immune responses.

61 an support trinitrophenyl (TNP)-LPS-specific mucosal immune responses.

62 ation, in general, does not induce effective mucosal immune responses, a mucosal HIV vaccine is urgen

63 ural exposure to pneumococci or have altered mucosal immune responses after colonization with this or

64 nd exogenous IL-12 significantly augment the mucosal immune response against the intracellular pathog

65 icrobes and may play a role in initiation of mucosal immune responses against commensal or transient

66 via a bacterial adjuvant that may potentiate mucosal immune responses against deadly pathogens.

67 ts and vaccine delivery mechanisms to induce mucosal immune responses against key bacterial antigens

68 e required for generation of protective lung mucosal immune responses against microbial pathogens.

69 hen given orally to induce both systemic and mucosal immune responses against poliovirus has resulted

70 (F) protein, understanding the importance of mucosal immune responses against RSV infection, and the

71 ective in eliciting the production of both a mucosal immune response and a systemic bactericidal anti

72 olonic inflammation caused by a dysregulated mucosal immune response and epithelial barrier disruptio

73 There was no significant correlation between mucosal immune response and most clinical factors.

74 gen sampling cells are known to initiate the mucosal immune response and to act as a site of entry fo

75 intestinal disease but can broadly activate mucosal immune responses and accelerate the onset and se

76 PBMC) populations were monitored weekly, and mucosal immune responses and bacterial loads were assess

77 le in antimicrobial and anticancer immunity, mucosal immune responses and effector functions of these

78 Defining mucosal immune responses and inflammation to candidate h

79 Because of their similarities to infants in mucosal immune responses and their susceptibility to hum

80 inoic acid administration fully restored the mucosal immune responses and vaccine protective efficacy

81 FMT on microbiota composition and function, mucosal immune response, and clinical outcome in patient

82 n-specific CD4(+) and CD8(+) T cells, primed mucosal immune responses, and enhanced protection from l

83 assively acquired antibodies, the active gut mucosal immune responses, and immunoglobulin A (IgA) coa

84 CCR5 coreceptor by HIV; 4) CTL activity; 5) mucosal immune responses; and 6) CD8 T cell responses th

85 Local mucosal immune responses are critical for protection fro

86 However, we demonstrate in this article that mucosal immune responses are evident at multiple mucosal

87 The strongest mucosal immune responses are induced following mucosal A

88 mental systems have been identified in which mucosal immune responses are induced following nonmucosa

89 Protective mucosal immune responses are thought best induced by tra

90 hoid follicles, inductive sites for adaptive mucosal immune responses, are covered by a follicle-asso

91 den of disease in humans has been redefined, mucosal immune responses associated with protection iden

92 t IBD is indeed characterized by an abnormal mucosal immune response but that microbial factors and e

93 ines and chemokines, which not only regulate mucosal immune responses but also regulate inflammatory

94 vaccine (IPV) does not induce an intestinal mucosal immune response, but could boost protection in c

95 Intestinal microbes induce homeostatic mucosal immune responses, but can also cause inappropria

96 - or anti-inflammatory roles in facilitating mucosal immune responses, but the relative contributions

97 rance to OVA in mice primed for a Th2-biased mucosal immune response by infection with the nematode p

98 of water and electrolytes and modulates the mucosal immune response by stimulating cellular synthesi

99 s and had strong evidence of anti-Salmonella mucosal immune responses by enzyme-linked immunospot stu

100 One strategy for the induction of mucosal immune responses by oral immunization is to admi

101 ht to evaluate the induction of systemic and mucosal immune responses by the use of Newcastle disease

102 inflammasome forming NLRs that modulate the mucosal immune response during inflammatory bowel diseas

103 of H1N1 influenza virus and associated host mucosal immune responses during acute infection in human

104 es, avidities, and functions of systemic and mucosal immune responses elicited by a vaccine regimen c

105 es that OMP CD is a target of a systemic and mucosal immune response following infection and coloniza

106 e response to goat anti-mouse IgD Ab and the mucosal immune response following oral inoculation with

107 ve intracellular bacterium, to study the gut mucosal immune responses following oral infection.

108 cyte supernatant (ALS, a surrogate marker of mucosal immune responses) from patients with severe chol

109 Studying vaccine-elicited mucosal immune responses has been problematic because of

110 Cholera toxin (CT) elicits a mucosal immune response in mice when used as a vaccine a

111 suggest that EBV manipulates and evades the mucosal immune response in oral epithelial infection.

112 ganism, could induce an anatomically distant mucosal immune response in reproductive tract tissues, t

113 y to accentuate the development of a humoral mucosal immune response in the gut, and we used oral col

114 The exact role of the mucosal immune response in the pathogenesis of human pap

115 viable model for future investigation of the mucosal immune response in the RALT and its relationship

116 that IL-10 is an important regulator of the mucosal immune response in vivo.

117 G ODN) as a combined nasal adjuvant elicited mucosal immune responses in aged (2-y-old) mice.

118 rtant for optimizing induction of anti-HIV-1 mucosal immune responses in both males and females.

119 Importantly, prominent mucosal immune responses in CCR7-deficient mice increase

120 hese cells remains unclear, we have compared mucosal immune responses in gamma/delta T cell receptor-

121 HIV-1 Env vaccine elicited both systemic and mucosal immune responses in humans.

122 provide important measures of HIV-1-specific mucosal immune responses in infected women.

123 binant protein, known to induce systemic and mucosal immune responses in mammalian systems, has been

124 bust antigen-specific cellular, humoral, and mucosal immune responses in many animal models of infect

125 n induced long-lived protective systemic and mucosal immune responses in mice when administered in th

126 gen was evaluated to induce the systemic and mucosal immune responses in mice.

127 vitro in addition to improving systemic and mucosal immune responses in mice.

128 bacteria stimulate protective or tolerogenic mucosal immune responses in normal (ie, resistant) hosts

129 n be used to stimulate strong virus-specific mucosal immune responses in primates.

130 The ability to generate specific mucosal immune responses in reproductive tract tissues a

131 erate with lymphocytes in the development of mucosal immune responses in the gastrointestinal tract.

132 the attractive property of inducing desired mucosal immune responses, including colostral antibodies

133 In this study, we sought to explore how mucosal immune responses influence HIF-dependent end poi

134 The gastric mucosal immune response is thought to be comprised predo

135 osal transmission, induction of an effective mucosal immune response is thought to be pivotal in prev

136 ular analysis of induction and regulation of mucosal immune responses, little is yet known about diff

137 t with a role for this pathway in generating mucosal immune responses, lung DC targeting by i.n. immu

138 Because mucosal immune responses may be important in protection

139 t that certain components of the innate oral mucosal immune response, most notably TLRs and inflammat

140 the plant tissues were simply fed to mice, a mucosal immune response occurred.

141 As a surrogate to compare mucosal immune responses of infant and adult lungs, rhes

142 iggers a Mycobacterium tuberculosis-specific mucosal immune response orchestrated by interleukin 17A

143 onse but also to the cell-mediated and local mucosal immune responses, particularly in naive ferrets.

144 ection impairs the IL-17 axis, an arm of the mucosal immune response preventing systemic microbial di

145 To study whether cruzipain could induce mucosal immune responses relevant for vaccine developmen

146 But whether or how this process controls mucosal immune responses remains unknown.

147 The identification of mucosal immune responses required for protection against

148 nal microbiota, mucus layer, bile acids, and mucosal immune responses, reveal potential mechanisms by

149 a, via a global T-helper type 2 (Th2)-biased mucosal immune response secondary to STH infection.

150 ric microflora are driving forces regulating mucosal immune responses, some of which are pathogenic a

151 The mucosal immune responses stimulated by T. cruzi gastric

152 .m. route induced a more potent systemic and mucosal immune response than a single immunization by ei

153 induces changes in the microbiota and in the mucosal immune response that can be beneficial to the ho

154 nd/or B7-2 ligand interactions on the type 2 mucosal immune response that follows oral infection of m

155 CD40/CD40 ligand interactions on the type 2 mucosal immune response that follows oral inoculation of

156 n of anti-CD3 to mice induces changes in the mucosal immune response that prevent colitis, independen

157 three mutant enterotoxins potentiated strong mucosal immune responses that were equivalent to the res

158 In the context of mucosal immune responses, the integrin alpha 4 beta 7 ha

159 by which IL-4 could amplify inflammation in mucosal immune responses through receptor systems for en

160 ic susceptibility, intestinal microflora and mucosal immune responses through the pattern recognition

161 The mechanisms underlying this dysregulated mucosal immune response to a soluble antigen have not be

162 if humans would also develop a serum and/or mucosal immune response to an antigen delivered in an un

163 The role of leptin in the mucosal immune response to Clostridium difficile colitis

164 with DH originates from the small bowel as a mucosal immune response to gluten ingestion.

165 We hypothesized that the mucosal immune response to gluten is responsible for the

166 ained when OVA is fed during the peak of the mucosal immune response to H. polygyrus.

167 nt consequences for our understanding of the mucosal immune response to invasive pathogens.

168 important implications in understanding the mucosal immune response to M. catarrhalis in the setting

169 Major differences occur in the mucosal immune response to pathogens and commensals.

170 tions between enterocytes, and enhancing the mucosal immune response to pathogens.

171 Defensins are part of the innate mucosal immune response to STIs and therefore we investi

172 ry bowel disease is caused by a dysregulated mucosal immune response to the intestinal microflora in

173 sults from an aberrant and poorly understood mucosal immune response to the microbiota of the gastroi

174 mmensal interaction, indirectly via the host mucosal immune response to the pathogen, or by a combina

175 Here we examined the mouse mucosal immune responses to 12 filamentous environmental

176 ed clinical trial, we evaluated systemic and mucosal immune responses to a candidate adenovirus serot

177 show that nasal nCT as an adjuvant enhances mucosal immune responses to a T cell-independent Ag due

178 ity are believed to be sites of induction of mucosal immune responses to airborne antigens.

179 nized by V cholerae and develop systemic and mucosal immune responses to antigens expressed by these

180 inistered vaccines induced both systemic and mucosal immune responses to coadministered Ags.

181 parasite-specific cell-mediated and humoral mucosal immune responses to determine what constitutes p

182 Mucosal immune responses to fungal infection range from

183 rectal mucosa has led to intensive study of mucosal immune responses to HIV and to the development o

184 choma pathogenesis, no studies have examined mucosal immune responses to hsp60 in populations for whi

185 ng of the importance of IL-10 in controlling mucosal immune responses to infectious challenges, we em

186 We characterized the role of Card9 in mucosal immune responses to intestinal epithelial injury

187 mouse model that permits the study of human mucosal immune responses to lung pathogens.

188 Mucosal immune responses to meningococcal conjugate and

189 sid protein (VRP-NV1) developed systemic and mucosal immune responses to Norwalk VLPs, as well as het

190 d with VRP-NV2 elicited reduced systemic and mucosal immune responses to Norwalk VLPs, demonstrating

191 Mucosal immune responses to pathogenic gut bacteria and

192 given mucosally, on the systemic and distal mucosal immune responses to plasmid DNA encoding gB of h

193 nce of IL-12 is able to enhance systemic and mucosal immune responses to pneumococci and efficiently

194 deeper understanding of the dysregulation of mucosal immune responses to the commensal intestinal org

195 To optimize mucosal immune responses to the HIV-1 peptide vaccine ca

196 essentially no studies to date have assessed mucosal immune responses to this disease.

197 The means by which mucosal immune responses to vaccine antigens are elicite

198 uring highly T helper 1 (Th1) cell-polarized mucosal immune responses, Treg cell numbers collapsed vi

199 stigates perturbation of the host intestinal mucosal immune response, using a model of human microbio

200 The mucosal immune response was characterized by morphometri

201 (CCR6) deficiency affects the generation of mucosal immune responses, we evaluated a potential role

202 n as mucosal adjuvant, and both systemic and mucosal immune responses were assessed.

203 sally immunized with cholera toxin (CT), and mucosal immune responses were compared with C57BL/6 mice

204 asal immunizations of guinea pigs, serum and mucosal immune responses were detected against both Shig

205 Anti-CFA/II mucosal immune responses were determined from the number

206 Serological and mucosal immune responses were evaluated in all vaccinate

207 The humoral and mucosal immune responses were further augmented if both

208 Increased antigen-specific mucosal immune responses were induced in the lungs and t

209 No mucosal immune responses were measurable when the immuno

210 , while CD8(+) T-cell antiviral activity and mucosal immune responses were not associated with delaye

211 Systemic and mucosal immune responses were robust in naive subjects i

212 hat these mice generated an intimin-specific mucosal immune response when primed parenterally and the

213 s to induce protective as well as pathogenic mucosal immune responses, with the type of response depe

214 Our studies reveal compartmentalized mucosal immune responses within the nasal mucosa of a ve